Irofulven second generation

N/A

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameIrofulven second generation
Drug Alias NameHydroxymethylacylfulveneIrofulven-2LP 184Irofulven-2STAR-001 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsRNA polymerase II inhibitorsApoptosis stimulants +[5] 
TargetsRNA polymerase IITopoisomerase II
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCentral Nervous System Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California San Diego
China Registration ClassN/A

Develop Information

Active CompaniesStarlight Therapeutics IncLantern Pharma Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCentral Nervous System Neoplasms +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A